AbTherx

What AbTherx does

AbTherx, Inc. is a private biotechnology company founded in 2023 and headquartered in Mountain View, California. The company commercializes the Atlas Mouse platform, a suite of proprietary transgenic mouse technologies designed for therapeutic antibody discovery. The platform is built on experience accumulated by its founding team at Medarex, where they developed the HuMAb Mouse technology credited with enabling 13 marketed therapeutics including Opdivo, YERVOY, and LIBTAYO. AbTherx's four core transgenic products — Full Human Diversity Mouse, Binary Fixed Light Chain Mouse, Long CDR3 Mouse, and VHH Transgenic Mice — are engineered to overcome limitations of legacy humanized antibody platforms, including access to buried epitopes on GPCRs and ion channels and chain pairing complexity in bispecific formats. All platforms are patent-pending and curated to avoid patented alleles and rare variants, supporting a clean freedom-to-operate position for licensees. A proprietary AI-based immunogen design capability is layered on top of the Long CDR3 platform to identify and immunize against less accessible epitopes.

The company monetizes its platform through a mix of technology licensing, co-discovery partnerships, milestone-based economics, and selective royalty arrangements, with flexible structures including milestone- and royalty-free options for early-stage partners. More than 25 partners have launched 75+ discovery programs using Atlas Mice, with named counterparties spanning top-10 pharmaceutical companies (Gilead Sciences, Zai Lab), clinical-stage biotechs (Dragonfly Therapeutics, Rondo Therapeutics, Spice Biotechnologies, GPCR Therapeutics), and early-stage ventures (Red Queen Bio, Wield Therapeutics). Distribution is hybrid: direct enterprise licensing managed by AbTherx's business development team, plus channel partnerships with The Jackson Laboratory as exclusive distributor for select models and Mosaic Biosciences as preferred service partner.

The company's first Atlas Mouse-derived therapeutic entered Phase 1 clinical development in Q1 2026, providing clinical validation within three years of founding. The team has continued to expand the platform through new product launches (VHH transgenic models, lambda fixed light chain variants) and ecosystem partnerships integrating complementary technologies such as Single Cell Technology's AbTheneum screening platform and Vaccinex's ActivMAb antigen expression technology. Gilead Sciences remains a foundational partner, holding both an exclusive license to the original transgenic mouse technologies (acquired June 2023 and expanded October 2024) and non-exclusive rights to future AbTherx-developed technologies. AbTherx has not disclosed institutional venture capital funding; the company is supported primarily by partnership economics and Gilead collaboration payments.

Name

AbTherx

Legal name

AbTherx, Inc.

Website

https://abtherx.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

AbTherx commercializes the Atlas Mouse platform, proprietary transgenic mouse technologies for therapeutic antibody discovery, licensing them to pharmaceutical and biotech partners for monoclonal and bispecific antibody programs against targets including GPCRs and ion channels.

Ownership category

akta.pro rank

Product category

Antibody Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Antibody discovery platforms
• Transgenic mouse technologies
• Bispecific antibody engineering
• Human antibody therapeutics
• Therapeutic antibody licensing

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Platform Licensing: Licensing of Atlas Mouse transgenic technologies to pharmaceutical and biotech companies for use at their sites or through designated service providers. Partners gain access to next-generation antibody discovery technologies with freedom-to-operate positioning.
2. Research Collaboration and Co-discovery: Co-discovery partnerships combining AbTherx's transgenic technologies with partner capabilities for multispecifics, GPCRs, and other challenging targets. Revenue generated through research payments, downstream clinical and commercial milestone payments, and royalty payments on net sales of products.
3. Milestone and Royalty Payments: Flexible business terms include milestone- and royalty-free structures, shared risk models where partners pay upon success, and traditional upfront plus milestone and royalty arrangements. Over 75 discovery programs across more than 25 partners generating milestone revenue potential.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

AbTherx develops and licenses the Atlas Mouse Platform, a suite of proprietary transgenic mouse technologies for therapeutic antibody discovery. The platform includes Full Human Diversity Mice, Binary Fixed Light Chain Mice, Long CDR3 Mice, and VHH Transgenic Mice that enable partners to discover fully human monoclonal, bispecific, and single-domain antibodies against challenging targets such as GPCRs and ion channels. AbTherx provides these technologies through direct licensing, co-discovery partnerships, and channel distribution via The Jackson Laboratory and Mosaic Biosciences.

Product overview

AbTherx offers the Atlas Mouse Platform, a comprehensive suite of proprietary transgenic mouse technologies for therapeutic antibody discovery. The platform comprises four core products: the Atlas Full Human Diversity Mouse for standard monoclonal antibody discovery with >99% human repertoire coverage; the Atlas Binary Fixed Light Chain Mouse (available in kappa-kappa and lambda-lambda configurations) for native-structure bispecific IgG development; the Atlas Long CDR3 Mouse for targeting buried epitopes in GPCRs and ion channels using naturally-occurring D-D fusion mechanisms; and the Atlas VHH Transgenic Mice for single-domain antibody generation. The platform is enhanced by proprietary AI-based immunogen design and is accessible through flexible partnership models ranging from milestone- and royalty-free structures to standard licensing.

Differentiator

Problem solved

Functional benefit

Products and services

• Atlas Full Human Diversity Mouse Patent-pending transgenic mouse engineered to capture a broad, human-like antibody response by sourcing VH and VK alleles representing >99% of the expressed human repertoire, providing higher hit rates, greater sequence diversity, improved binding profiles, and enhanced hybridoma stability compared to other top transgenic platforms.
• Atlas Binary Fixed Light Chain (BFLC) Mouse Patent-pending transgenic mouse engineered with two fixed light chain options (kappa-kappa or lambda-lambda) on a background of full human diversity for the heavy chain, enabling native-structure bispecific IgGs with best-in-class hit rates, strong freedom-to-operate position, and improved manufacturability and developability.
• Atlas Long CDR3 Mouse Patent-pending transgenic mouse generating fully human antibodies with long CDR3 regions via a naturally-occurring D-D fusion mechanism, unlocking access to buried epitopes within GPCRs, ion channels, and other challenging targets while minimizing developability and immunogenicity risks.
• Atlas VHH Transgenic Mice Human VHH transgenic models designed to deliver superior developability and broader sequence diversity for single-domain antibodies, providing building blocks for advanced multispecifics, cell therapies, and complex modalities.
• AI-Based Immunogen Design Proprietary AI-based immunogen design and expression technology used in conjunction with the Atlas Long CDR3 Mouse platform to identify and immunize against novel targets and epitopes that may have been buried or less accessible to traditional humanized models.
• Atlas Platform Licensing and Co-Discovery Partnerships Flexible partnership offerings including direct platform licensing for in-house use of Atlas Mouse technologies and co-discovery collaborations combining AbTherx's platform expertise with partner therapeutic focus areas, with business terms ranging from milestone- and royalty-free structures to shared risk models and standard licensing.

Quantifiable outcome

• Superior performance in head-to-head transgenic platform comparison studies
• +4 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and major.

• FairJourney BiocoreStrategic or Co-development Partner · 1 June 2026FairJourney Bio partnered with AbTherx to integrate transgenic mouse-based antibody discovery technologies in-house, enabling partner programs to run from immunisation to a developability-assessed lead in a single continuous workflow. FairJourney Bio gained access to AbTherx's Atlas Full Human Diversity and Common Light Chain mouse technologies, feeding into FairJourney Bio's B-Cell Navigator platform across global sites in Porto, Cambridge, and San Diego. The partnership was announced at BIO International Convention 2026 as FairJourney Bio expands its US presence and capabilities.
• Red Queen BiomajorStrategic or Co-development Partner · 8 January 2026Therapeutic antibody discovery and development partnership combining AbTherx's Atlas Full Human Diversity Transgenic Mouse platform with Red Queen Bio's vaccination and AI-driven antibody development pipeline. Partnership already generated high-quality, AI-ready data in less than three months. Focused on generating antibodies against Red Queen Bio-selected targets for biodefense and national biosecurity applications.
• Dragonfly TherapeuticscoreStrategic or Co-development Partner · 23 September 2025Expanded partnership with Dragonfly Therapeutics following successful multi-target pilot study comparing transgenic platforms. The evaluation demonstrated superior performance of Atlas Full Human Diversity Mice with superior hit rates, antibody diversity, binding profiles, and hybridoma stability. Dragonfly gains access to Atlas Mouse platform to accelerate discovery of novel therapeutic antibodies across its innovative therapeutics pipeline.
• GPCR TherapeuticscoreStrategic or Co-development Partner · 16 June 2025Research collaboration to discover and develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs) for one target with potential to expand. Leverages AbTherx's patent-pending Atlas Long CDR3 Mouse to access buried epitopes within GPCRs, combined with GPCR Therapeutics' deep expertise in GPCR biology for cancer, fibrosis, and obesity treatments. Partnership expected to yield a pre-clinical asset with 50/50 ownership structure.
• Wield TherapeuticsmajorStrategic or Co-development Partner · 10 June 2025Antibody discovery partnership leveraging AbTherx's Atlas Full Human Diversity Transgenic Mouse technology to deliver antibodies against Wield-selected targets for autoimmune disease applications. AbTherx's efficient research planning enabled concept-to-collaboration within weeks. Wield has rights to develop and commercialize resulting therapeutic antibodies.
• Single Cell Technology and VaccinexmajorStrategic or Co-development Partner · 13 May 2025Multi-party collaboration incorporating Vaccinex's ActivMAb Technology into Atlas Mouse and AbTheneum antibody discovery platforms. ActivMAb enables expression of functional, properly folded complex proteins such as GPCRs and ion channels on poxvirus membrane for antibody discovery. Single Cell Technology applies its AbTheneum single B cell screening platform to mine differentiated antibodies from Atlas Mice.
• Spice BiotechnologiesmajorStrategic or Co-development Partner · 12 May 2025Multi-program antibody discovery partnership leveraging AbTherx's suite of Atlas Mouse technologies to deliver antibodies against Spice Bio-selected targets for next-generation immunotherapy drugs. Spice Bio founded by Alan J. Korman, who led discovery of YERVOY and OPDIVO at Bristol Myers Squibb.
• Rondo TherapeuticsmajorTechnology or Integration · 23 April 2025Technology license agreement leveraging AbTherx's Atlas Binary Fixed Light Chain Transgenic Mouse technology to deliver antibodies for Rondo's pipeline of bispecific antibodies targeting solid tumors. Fixed light chain technology streamlines bispecific antibody engineering with optimized heavy-light chain pairing.
• The Jackson Laboratory (JAX)coreChannel Partner/ Reseller/ Distributor · 9 May 2024Strategic partnership for co-development and commercialization of Atlas Mouse models. JAX serves as exclusive distributor of select Atlas Mouse models including Full Human Diversity Mouse and Binary Fixed Light Chain Mouse. Early access program launched H2 2024. Partnership combines JAX's expertise in mouse model development with AbTherx's antibody discovery capabilities.
• Single Cell TechnologymajorTechnology or Integration · 13 March 2024Partnership providing AbTherx and Atlas Mice licensees access to Single Cell Technology's proprietary single B cell screening engine (AbTheneum). Collaboration enables mining of larger arrays of B cells from Atlas Mice for therapeutic antibodies. AbTheneum compresses campaign timelines and captures all binder and non-binder screening and sequencing data in three weeks from cells to screened antibody sequences.
• Gilead SciencescoreTechnology or Integration · 7 June 2023License agreement providing AbTherx worldwide rights to Gilead's novel transgenic mouse technologies, which were developed by three AbTherx founders. AbTherx commercializes these technologies as Atlas Mice. The agreement was expanded in October 2024 to include development of additional transgenic mouse technologies and performance of additional therapeutic antibody research programs. Gilead retains non-exclusive rights to future AbTherx-developed transgenic mouse technologies.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Ligand Pharmaceuticals: Ligand's OmniAb platform offers transgenic and single-domain antibody discovery technologies (acquired Trianni, Harbour Antibodies, and xCella). OmniAb is the most direct multi-platform competitor to AbTherx's Atlas Mouse suite, serving similar pharma and biotech customers with antibody discovery partnerships.
• Alloy Therapeutics: Alloy offers a discovery services and platform-licensing model including the ATX-Gx transgenic mouse platform. AbTherx's CSO John Lippincott was previously SVP at Alloy. Both companies provide antibody discovery platforms and services to pharma partners.
• Adimab: Adimab is a leading antibody discovery services and platform company using yeast-based in vitro display rather than transgenic mice. It serves the same pharma and biotech customer base with discovery partnerships, representing the principal in vitro alternative to AbTherx's in vivo platform.
• FairJourney Bio: FairJourney Bio is an antibody discovery CRO with sites in Porto, Cambridge, and San Diego. It is both a partner of AbTherx (integrating Atlas Mice into its B-Cell Navigator workflow) and a competitor in end-to-end antibody discovery services for biotech and pharma clients.
• AlivaMab Discovery Services: AlivaMab provides antibody discovery services leveraging the AlivaMab Mouse platform. AbTherx's CEO Justin Mika previously led AlivaMab through rapid growth. Both companies offer transgenic-mouse-based antibody discovery services to pharma and biotech.

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron's VelocImmune transgenic mouse platform is the most established human antibody discovery platform, generating FDA-approved antibodies including Dupixent, Libtayo, and Praluent. AbTherx's founders developed the HuMAb Mouse at Medarex, a predecessor to VelocImmune's lineage.
• Genmab: Genmab developed the DuoBody, HexaBody, and HexElect bispecific/multispecific antibody platforms underlying approved drugs (RYBREVANT, EPKINLY, TECVAYLI, TALVEY). AbTherx's Scientific Advisor Janine Schuurman co-invented these technologies. Genmab is the gold standard for bispecifics that AbTherx's BFLC mice target.

Emerging players

• Crescendo Biologics: Crescendo develops T cell engagers and Humabody VHH single-domain antibodies for oncology. It represents an emerging competitor in the VHH/nanobody space that AbTherx is now entering with its Atlas VHH Transgenic Mouse launched in June 2026.
• Twist Bioscience: Twist offers synthetic antibody libraries and discovery services as an alternative to transgenic mouse platforms. It represents an emerging in silico/synthetic library approach that competes with AbTherx's in vivo discovery for partners prioritizing speed and scalability.
• Atreca: Atreca applies immune repertoire analysis and discovery platforms to identify novel antibodies from natural human immune responses. It is an emerging player in the antibody discovery space, offering an alternative platform approach to transgenic mouse-based discovery like AbTherx's Atlas Mice.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/abtherx

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AbTherx